140 related articles for article (PubMed ID: 4607196)
1. The importance of the ascending dopaminergic systems to the extrapyramidal and mesolimbic brain areas for the cataleptic action of the neuroleptic and cholinergic agents.
Costall B; Naylor RJ
Neuropharmacology; 1974 May; 13(5):353-64. PubMed ID: 4607196
[No Abstract] [Full Text] [Related]
2. Catalepsy and circling behaviour after intracerebral injections of neuroleptic, cholinergic and anticholinergic agents into the caudate-putamen, globus pallidus and substantia nigra of rat brain.
Costall B; Naylor RJ; Olley JE
Neuropharmacology; 1972 Sep; 11(5):645-63. PubMed ID: 4597256
[No Abstract] [Full Text] [Related]
3. Is there a relationship between the involvement of extrapyramidal and mesolimbic brain areas with the cataleptic action of neuroleptic agents and their clinical antipsychotic effect?
Costall B; Naylor RJ
Psychopharmacologia; 1973; 32(2):161-70. PubMed ID: 4796282
[No Abstract] [Full Text] [Related]
4. Extrapyramidal and mesolimbic involvement with the stereotypic activity of D- and L-amphetamine.
Costall B; Naylor RJ
Eur J Pharmacol; 1974 Feb; 25(2):121-9. PubMed ID: 4474081
[No Abstract] [Full Text] [Related]
5. Involvement of mesolimbic and extrapyramidal nuclei in the motor depressant action of narcotic drugs.
Costall B; Fortune DH; Naylor RJ
J Pharm Pharmacol; 1978 Sep; 30(9):566-72. PubMed ID: 29096
[No Abstract] [Full Text] [Related]
6. A comparison of the abilities of typical neuroleptic agents and of thioridazine, clozapine, sulpiride and metoclopramide to antagonise the hyperactivity induced by dopamine applied intracerebrally to areas of the extrapyramidal and mesolimbic systems.
Costall B; Naylor RJ
Eur J Pharmacol; 1976 Nov; 40(1):9-19. PubMed ID: 791660
[TBL] [Abstract][Full Text] [Related]
7. Mesolimbic involvement with behavioural effects indicating antipsychotic activity.
Costall B; Naylor RJ
Eur J Pharmacol; 1974 Jun; 27(1):46-58. PubMed ID: 4604756
[No Abstract] [Full Text] [Related]
8. Dopamine-acetylcholine-GABA neuronal linkages in the extrapyramidal and limbic systems.
McGeer PL; McGeer EG; Hattori T
Adv Biochem Psychopharmacol; 1977; 16():397-402. PubMed ID: 329651
[No Abstract] [Full Text] [Related]
9. Interaction of dopaminergic and cholinergic neurons in the extrapyramidal and limbic systems.
Bartholini G; Stadler H; Gadea-Ciria M; Lloyd KG
Adv Biochem Psychopharmacol; 1977; 16():391-5. PubMed ID: 18888
[No Abstract] [Full Text] [Related]
10. Effect of muscarinic cholinergic drugs on morphine-induced catalepsy, antinociception and changes in brain dopamine metabolism.
Kaakkola S; Ahtee L
Psychopharmacology (Berl); 1977 Mar; 52(1):7-15. PubMed ID: 403561
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of dopaminergic activity in the extrapyramidal and limbic systems by gamma-acetylenic GABA [proceedings].
Huot S; Lippert B; Palfreyman MG; Schechter PJ
Br J Pharmacol; 1977 Jun; 60(2):264P-265P. PubMed ID: 880435
[No Abstract] [Full Text] [Related]
12. [The antipsychotic action of neuroleptics and basal ganglia function].
Arushanian EB
Farmakol Toksikol; 1973; 26(4):481-9. PubMed ID: 4151298
[No Abstract] [Full Text] [Related]
13. Differences in the nature of the stereotyped behaviour induced by aporphine derivatives in the rat and in their actions in extrapyramidal and mesolimbic brain areas.
Costall B; Naylor RJ; Neumeyer JL
Eur J Pharmacol; 1975 Mar; 31(1):1-16. PubMed ID: 1168579
[TBL] [Abstract][Full Text] [Related]
14. Proceedings: Interaction of neuroleptic and cholinergic drugs with central dopaminergic mechanisms.
Kelly P; Miller RJ; Sahakian B
Br J Pharmacol; 1974 Nov; 52(3):430P-431P. PubMed ID: 4477511
[No Abstract] [Full Text] [Related]
15. The role of dopamine in pilocarpine-induced catalepsy.
Ahtee L; Kääriäinen I
Naunyn Schmiedebergs Arch Pharmacol; 1974; 284(1):25-38. PubMed ID: 4279348
[No Abstract] [Full Text] [Related]
16. Neuroleptic action of quaternary chlorpromazine and related drugs injected into various brain areas in rats.
Fog RL; Randrup A; Pakkenberg H
Psychopharmacologia; 1968; 12(5):428-32. PubMed ID: 5749325
[No Abstract] [Full Text] [Related]
17. Evidence for an inhibitory gabergic control of the meso-limbic dopamine neurons: possibility of improving treatment of schizophrenia by combined treatment with neuroleptics and gabergic drugs.
Fuxe K; Hökfelt T; Ljungdahl A; Agnati L; Johansson O; Perez de la Mora M
Med Biol; 1975 Jun; 53(3):177-83. PubMed ID: 1160412
[TBL] [Abstract][Full Text] [Related]
18. Dopaminergic and cholinergic interaction in cataleptic responses in mice.
Ushijima I; Kawano M; Kaneyuki H; Suetsugi M; Usami K; Hirano H; Mizuki Y; Yamada M
Pharmacol Biochem Behav; 1997 Sep; 58(1):103-8. PubMed ID: 9264077
[TBL] [Abstract][Full Text] [Related]
19. Functions of dopamine in the extrapyramidal and limbic systems. Clues for the mechanism of drug actions.
Di Chiara G; Morelli M; Acquas E; Carboni E
Arzneimittelforschung; 1992 Feb; 42(2A):231-7. PubMed ID: 1586394
[TBL] [Abstract][Full Text] [Related]
20. Central monoaminergic pathways with emphasis on their relation to the so called 'extrapyramidal motor system'.
Fuxe K; Hökfelt T; Olson L; Ungerstedt U
Pharmacol Ther B; 1977; 3(2):169-210. PubMed ID: 413120
[No Abstract] [Full Text] [Related]
[Next] [New Search]
